Drug Accumulation: When Repeated Doses Build Up

Take a compound twice and one of two things happens. Either the second dose lands on top of leftovers from the first and levels climb, or the first dose has mostly gone by the time the second arrives, and each dose behaves as if it were the only one. Which case you are in is not a mystery or a matter of the compound being “strong.” It comes down to a single comparison: how long the compound lasts versus how often you take it. That relationship is captured by the accumulation ratio, and you can read it off directly in the Dose Interval Visualizer.

What accumulation is, and isn’t

Accumulation means that at steady state, the compound sits at a higher level than a single dose would produce, because carryover from previous doses stacks up. It is not a sign of danger by itself, and it is not the same as the compound “being strong.” A drug can accumulate heavily and be well tolerated, or barely accumulate and still be potent. Accumulation is a statement about how repeated doses overlap in time.

The intuition: between two doses, your body clears some fraction of what is present. If it clears almost all of it before the next dose, there is little to carry forward and levels stay near the single-dose range. If it clears only a little, most of each dose is still around when the next arrives, and the total climbs, until faster clearance at the higher level rebalances it at steady state.

The accumulation ratio, in plain terms

The extent of build-up is summarized by the accumulation ratio:

Accumulation ratio = 1 / (1 - e^(-λτ))

where λ is the elimination rate constant (0.693 divided by the half-life) and τ is the dosing interval. You do not need to compute it by hand (the visualizer does), but the behavior is easy to read:

• The term e^(-λτ) is the fraction of a dose remaining at the end of one interval.
• 1 - e^(-λτ) is the fraction cleared during the interval.
• One divided by that fraction is the ratio. Clear only a small slice each interval, and you divide by a small number: a large ratio.

What matters is the ratio of half-life to interval, not either one alone. A useful shortcut: if the dosing interval equals one half-life, the accumulation ratio is 2: steady-state levels average about twice a single dose. Dose more often than the half-life and it rises above 2; dose far less often and it drops toward 1 (no meaningful accumulation).

Dosing interval relative to half-life	Fraction cleared per interval	Accumulation ratio
Interval = ¼ half-life (very frequent)	~16%	~5.3×
Interval = ½ half-life	~29%	~3.4×
Interval = 1 half-life	50%	2.0×
Interval = 2 half-lives	75%	~1.3×
Interval = 3 half-lives	~88%	~1.1×
Interval = 4+ half-lives (far apart)	~94%+	~1.0× (negligible)

When doses build up, and when they barely do

The table maps onto two ends of a spectrum.

Frequent relative to half-life → real accumulation. Continuous infusions and multiple-daily-dose regimens sit here. Each dose lands well before the last has cleared, so levels stack several-fold above a single dose before plateauing. This is often intentional: it is how you hold a compound in its effective window without giant individual doses.

Far apart relative to half-life → almost no accumulation. If you dose at intervals several times the half-life, each dose has mostly washed out before the next, so every dose rises and falls on its own. The “steady state” here is just a repeat of the single-dose profile, with deep troughs between doses.

Most weekly GLP-1 protocols sit in an interesting middle. Semaglutide’s ~1-week half-life dosed once weekly means the interval is roughly one half-life, so it accumulates modestly (a ratio near 2) and rides at a relatively smooth level, which is part of why weekly dosing works. A daily compound with a multi-day half-life, by contrast, accumulates much more. This is also why you cannot infer accumulation from half-life alone: the same compound accumulates differently depending on how often it is dosed.

A caution: terminal half-life can mislead

One real-world wrinkle: the “half-life” quoted for a compound is often the terminal half-life, measured as levels tail off after a dose. For some drugs that terminal phase carries only a small fraction of the compound, and it overpredicts how much accumulates with repeated dosing. Pharmacologists have proposed an “operational” multiple-dosing half-life because terminal half-life can grossly mispredict real accumulation. Practically: treat any single accumulation estimate as an approximation, especially for compounds with complex, multi-phase clearance.

The takeaway

Whether repeated doses build up is decided by half-life relative to dosing interval, and the accumulation ratio 1/(1 - e^(-λτ)) puts a number on it. Dose frequently compared to how fast you clear and levels stack several-fold; dose far apart and each dose stands nearly alone. Accumulation controls how high the plateau sits, not how long it takes to get there; that is always about 4-5 half-lives. And accumulation is not the same as fluctuation: two compounds can share an accumulation ratio yet swing differently between doses, as covered in Peaks, Troughs, and Fluctuation.

Enter a half-life and interval in the Dose Interval Visualizer to see the accumulation ratio and plateau for any schedule, and use the Peptide Half-Life Visualizer to see the single-dose decay it builds on.

This article is educational and not medical advice. Many research peptides are not approved for human use; dosing decisions belong with a qualified clinician.

Sources

• Elimination Half-Life of Drugs — StatPearls (NCBI Bookshelf)
• The Operational Multiple Dosing Half-life: A Key to Defining Drug Accumulation (Pharmaceutical Research, 2008 — PMC)
• Pharmacokinetic Considerations for Repeat Dosing — Allucent